Biogen CEO says $56,000 yearly for Alzheimer’s drug is ‘honest,’ guarantees to not hike…
Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is…